Related Experiment Video
Updated: Oct 2, 2026
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Soluble CD30 in pediatric patients with atopic dermatitis
A Frezzolini1, M Paradisi, M Ruffelli
1Department of Immunodermatology, Istituto Dermopatico dell'Immacolata-IDI, IRCCS, Rome, Italy.
Insights
Soluble CD30 (sCD30) levels are elevated in children with atopic dermatitis (AD), correlating with disease severity. This suggests sCD30 is a valuable marker for assessing Th2 immune responses and disease activity in pediatric AD.
Area of Science:
- Immunology
- Dermatology
- Pediatrics
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition.
- T-helper 2 (Th2) cells are implicated in AD pathogenesis.
- Soluble CD30 (sCD30) is an activation marker for Th2-producing T-cell clones.
Purpose of the Study:
- To investigate serum sCD30 levels in pediatric AD patients.
- To correlate sCD30 levels with AD severity and other immune markers.
Main Methods:
- Serum samples were collected from pediatric AD patients (n=25), healthy donors (n=20), and urticaria patients (n=10).
- Disease severity was assessed using SCORAD and Costa et al. scoring systems.
- Serum sCD30 and soluble interleukin-2 receptor (sIL-2R) levels were measured.
Main Results:
- Serum sCD30 levels were significantly higher in AD patients compared to controls.
- A positive correlation was found between serum sCD30 and clinical AD severity scores.
- A significant association was observed between sCD30 and sIL-2R levels in AD patients.
Conclusions:
- Elevated sCD30 in pediatric AD confirms its role as an in vivo marker of Th2 immune response.
- sCD30 correlates with clinical disease activity and sIL-2R levels.
- sCD30 serves as an additional marker for evaluating disease activity in pediatric AD.
Abstract:
Atopic dermatitis (AD) is a chronic, inflammatory skin disease in which a pathogenetic role of Th2 cells has been supposed. This study investigated the presence of soluble CD30 (sCD30), an activation marker of T-cell clones able to produce Th2-type cytokines, in sera from pediatric patients affected by AD (n = 25) with no symptoms of asthma or rhinitis. The severity of the disease was graded by both the SCORAD and Costa et al. clinical scoring systems. Serum levels of sCD30 were significantly higher in patients with AD in respect to both normal donors (n = 20) and urticaria patients (n = 10), and a positive correlation between serum sCD30 and clinical score was found (r = 0.508; P = 0.01) when AD patients were evaluated by Costa et al.'s method. Furthermore, a significant association (r = 0.443; P = 0.027) between sCD30 and serum levels of the soluble interleukin (IL)-2 receptor (sIL-2R) was observed in AD. The presence of high amounts of sCD30 in atopic patients seems to confirm the role of this molecule as an activation marker useful for in vivo evaluation of a Th2 immune response, and the correlation observed with both clinical score and sIL-2R levels indicates the role of sCD30 as an additional marker of disease activity in pediatric patients with AD.
